CA2920066A1 - Marker for statin treatment stratification in heart failure - Google Patents

Marker for statin treatment stratification in heart failure Download PDF

Info

Publication number
CA2920066A1
CA2920066A1 CA2920066A CA2920066A CA2920066A1 CA 2920066 A1 CA2920066 A1 CA 2920066A1 CA 2920066 A CA2920066 A CA 2920066A CA 2920066 A CA2920066 A CA 2920066A CA 2920066 A1 CA2920066 A1 CA 2920066A1
Authority
CA
Canada
Prior art keywords
patient
biomarker
level
sample
statin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2920066A
Other languages
English (en)
French (fr)
Inventor
Dirk Block
Hanspeter Brunner
Thomas Dieterle
Ursula-Henrike Wienhues-Thelen
Christian Zaugg
Andre Ziegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2920066A1 publication Critical patent/CA2920066A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2920066A 2013-08-26 2014-08-26 Marker for statin treatment stratification in heart failure Abandoned CA2920066A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13181687.8 2013-08-26
EP13181687.8A EP2843414B1 (en) 2013-08-26 2013-08-26 Marker for statin treatment stratification in heart failure
PCT/EP2014/068090 WO2015028469A2 (en) 2013-08-26 2014-08-26 Marker for statin treatment stratification in heart failure

Publications (1)

Publication Number Publication Date
CA2920066A1 true CA2920066A1 (en) 2015-03-05

Family

ID=49029008

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2920066A Abandoned CA2920066A1 (en) 2013-08-26 2014-08-26 Marker for statin treatment stratification in heart failure

Country Status (6)

Country Link
US (3) US10234464B2 (cg-RX-API-DMAC10.html)
EP (2) EP2843414B1 (cg-RX-API-DMAC10.html)
JP (3) JP6625535B2 (cg-RX-API-DMAC10.html)
CN (2) CN105659095B (cg-RX-API-DMAC10.html)
CA (1) CA2920066A1 (cg-RX-API-DMAC10.html)
WO (1) WO2015028469A2 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
CN106018789A (zh) * 2016-08-03 2016-10-12 北京德奥平生物技术有限公司 一种st2定量检测方法及试剂盒
WO2018167447A1 (en) 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
US11942219B1 (en) * 2017-09-25 2024-03-26 Cerner Innovation, Inc. Determining a cardiovascular ischemic event and decision support tool
EP3899035B1 (en) * 2018-12-20 2025-04-16 F. Hoffmann-La Roche AG Detection of target nucleic acid by solid-phase molography
CN110361544A (zh) * 2019-07-29 2019-10-22 清华大学深圳研究生院 P1np检测试纸、p1np检测试剂盒和检测方法
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5695761A (en) 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
US6414219B1 (en) 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
CA2372119A1 (en) 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
CA2509063C (en) * 2002-11-16 2010-11-02 Dade Behring Marburg Gmbh Scd40l and placental growth factor (plgf) as biochemical marker combinations in cardiovascular diseases
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
EP1929295A4 (en) * 2005-08-30 2010-03-17 Biosite Inc USE OF SOLUBLE FLT-1 AND ITS FRAGMENTS IN CARDIOVASCULAR CONDITIONS
WO2007026214A1 (en) 2005-08-31 2007-03-08 Inverness Medical Switzerland Gmbh Predicting responses to drugs or drug candidates
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
KR101245877B1 (ko) 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
EP1884777A1 (en) * 2006-08-04 2008-02-06 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on GDF-15
DK2115477T3 (en) * 2007-01-25 2015-08-10 Hoffmann La Roche USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE
WO2009040133A1 (en) * 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
ES2457529T3 (es) 2007-10-10 2014-04-28 F. Hoffmann-La Roche Ag Medios y métodos para controlar el infarto de miocardio y su tratamiento
CA2703979A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic ether and thioether derivatives and methods of use thereof
WO2009079773A1 (en) * 2007-12-21 2009-07-02 Mcmaster University Method for assessing risk of heart failure
BRPI0819519A2 (pt) * 2007-12-31 2015-05-26 Univ Emory Análogos de triarilmetano e seus usos no tratamento de cânceres.
US8632764B2 (en) * 2008-04-30 2014-01-21 University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
JP2011523044A (ja) * 2008-05-15 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー 拡張型心筋症の区別のための及び特異的治療とその結果の基礎としてのマルチマーカーパネル
JP2011522239A (ja) * 2008-05-29 2011-07-28 エフ．ホフマン−ラ ロシュ アーゲー 心筋トロポニン、ｓＣＤ４０ＬおよびＣ反応性タンパク質の測定に基づく心臓療法に感受性の被験体を特定する手段および方法
WO2010048346A1 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102203606A (zh) * 2008-10-30 2011-09-28 公共健康研究中心 生物标记物
WO2010057135A2 (en) * 2008-11-14 2010-05-20 The Regents Of The University Of California Methods and compositions for predicting a subject's susceptibility to and risk of developing type 2 diabetes
CN102422157B (zh) * 2009-04-27 2014-10-29 霍夫曼-拉罗奇有限公司 内皮抑制素作为心力衰竭标记的应用
EP2504705B1 (en) * 2009-11-27 2017-04-12 Roche Diagnostics GmbH Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction
WO2011126808A2 (en) * 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2588111A1 (en) * 2010-07-02 2013-05-08 BG Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
EP2367006A1 (en) * 2010-08-24 2011-09-21 Roche Diagnostics GmbH PLGF-based means and methods for diagnosing cardiac causes in acute inflammation
WO2012028713A1 (en) * 2010-09-02 2012-03-08 Roche Diagnostics Gmbh Method for diagnosing and monitoring the cardiac pathophysiological state in a subject undergoing or having undergone percutaneous coronary intervention (pci)
JP2014505259A (ja) * 2011-02-03 2014-02-27 アボット・ラボラトリーズ 慢性心不全における予後診断および診断の方法

Also Published As

Publication number Publication date
US11460474B2 (en) 2022-10-04
US20160169911A1 (en) 2016-06-16
EP2843414A1 (en) 2015-03-04
JP6934508B2 (ja) 2021-09-15
EP3441768A3 (en) 2019-03-20
CN105659095B (zh) 2019-11-05
JP6625535B2 (ja) 2019-12-25
JP2016529505A (ja) 2016-09-23
US10234464B2 (en) 2019-03-19
WO2015028469A2 (en) 2015-03-05
JP2021185371A (ja) 2021-12-09
HK1225443A1 (zh) 2017-09-08
US20220206015A1 (en) 2022-06-30
WO2015028469A3 (en) 2015-05-07
EP3441768A2 (en) 2019-02-13
CN110658344A (zh) 2020-01-07
JP2020046432A (ja) 2020-03-26
EP2843414B1 (en) 2018-09-19
CN105659095A (zh) 2016-06-08
US20190154706A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
US12117454B2 (en) Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
US20220206015A1 (en) Marker for statin treatment stratification in heart failure
JP6756772B2 (ja) 心不全の治療選択におけるバイオマーカー
CN106461672B (zh) 用于诊断舒张功能障碍的igfbp7
CN105785053B (zh) 风险患者和中风原因的基于肌钙蛋白和bnp的诊断
HK40012676A (en) Marker for statin treatment stratification in heart failure
HK1225443B (en) Marker for statin treatment stratification in heart failure
HK40012159A (en) Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
HK1228997A1 (en) Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
HK1228997B (en) Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
HK1234493B (en) Igfbp7 for diagnosing diastolic dysfunction
HK1213324B (en) Biomarkers in the selection of therapy of heart failure

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160201

FZDE Discontinued

Effective date: 20240415